Mounting evidence indicates that both hematologic and
solid tumors are heterogeneous disorders with diverse
genomic aberrations [1-3]. Due to the extensive investigations of the correlation between genomic instability
and disease pathogenesis conducted over the last two
decades, an increasing number of genomic abnormalities
such as gain, loss or rearrangement of chromosomal
fragments and gene mutations, have been found to be
driving factors in the pathogenesis of various malignancies. Over the time, a series of cutting-edge cytogenetic
and molecular tests have been developed for detecting
such genomic aberrations, which allows more accurate
molecular profiling for individual patients. The advanced
molecular pathology techniques [4] enable better disease
stratification and prognosis, leading to tailored therapeutic regimens. Apparently, a new era of personalized
medicine has arrived much earlier than most of us
expected